APA (7th ed.) Citation

Garon, E. B., & Thomas, M. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. The lancet, 384(9944), . https://doi.org/10.1016/S0140-6736(14)60845-X

Chicago Style (17th ed.) Citation

Garon, Edward B., and Michael Thomas. "Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel for Second-line Treatment of Stage IV Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy (REVEL): A Multicentre, Double-blind, Randomised Phase 3 Trial." The Lancet 384, no. 9944 (2014). https://doi.org/10.1016/S0140-6736(14)60845-X.

MLA (9th ed.) Citation

Garon, Edward B., and Michael Thomas. "Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel for Second-line Treatment of Stage IV Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy (REVEL): A Multicentre, Double-blind, Randomised Phase 3 Trial." The Lancet, vol. 384, no. 9944, 2014, https://doi.org/10.1016/S0140-6736(14)60845-X.